Company
Ahead Together
We unite science, technology and talent to get ahead of disease together.
Purpose, strategy and culture
Getting ahead of disease is one of the greatest, most inspiring challenges there is on the planet. By pursuing this purpose together, we have the scale and expertise to positively impact the health of 2.5 billion people by the end of the decade. In doing so, we will deliver stronger and more sustainable growth as a company where people can thrive.
At a glance
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.
View our policy positions
We have policies in place across GSK to ensure we meet the high standards we set ourselves as a company, and those that are expected of us externally.
Learn more about our views and our practices across a range of issues that are important to GSK, our patients and our stakeholders.
Latest press releases
- GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S.
- New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
- ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024